N-Acetyl Semax Amidate: A Stabilised ACTH(4-10)-Derived Heptapeptide

Research summary. N-Acetyl Semax Amidate is a chemically protected analogue of Semax, a synthetic heptapeptide originally developed in Russia as an analogue of adrenocorticotropic hormone (ACTH) fragment 4-10. The N-acetyl C-amide modifications cap both peptide termini, extending stability against aminopeptidase and carboxypeptidase clearance and producing an analogue with reportedly improved blood-brain-barrier penetration relative to the unmodified parent. Semax holds approved status as a CNS-active peptide in Russia but is not approved by the FDA or EMA. The N-acetyl amidated derivative is correspondingly an investigational research analogue of an already region-specific compound.

Molecular profile

• Sequence: Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂ (Ac-MEHFPGP-NH₂)
• Molecular formula: C₃₇H₅₁N₉O₁₀S
• Molecular weight: ~858.98 g/mol
• Class: Stabilised heptapeptide; ACTH(4-10) analogue
• Distinction from parent: Semax itself is the heptapeptide MEHFPGP without N-terminal acetylation or C-terminal amidation; the N-acetyl amidated derivative is the chemically capped analogue.

Origin and biological context

Semax was developed in the laboratory of Ivan Ashmarin and colleagues at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is built on the ACTH(4-10) fragment Met-Glu-His-Phe-Pro-Gly-Pro, the portion of the ACTH molecule responsible for the well-known "behavioural" effects of ACTH that are dissociable from its steroidogenic activity at the adrenal cortex. Adding an additional Pro-Gly-Pro tail to ACTH(4-10) (the original Semax design) produces a peptide with extended in vivo activity. The N-acetyl C-amide modifications further cap the peptide termini against exopeptidase clearance.

Mechanism of action

Semax and its N-acetyl amidated analogue are interpreted as acting through several proposed mechanisms:

• BDNF and neurotrophic factor modulation. Increases in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression have been reported in rodent CNS following Semax administration, with associated effects on hippocampal and cortical gene-expression patterns.
• Monoaminergic modulation. Reported effects on serotonin and dopamine handling provide a candidate mechanism for the cognition- and mood-related preclinical findings.
• Default-mode-network and resting-state connectivity. Functional MRI studies have reported changes in resting-state network activity following Semax administration, interpreted as engagement of the default-mode network.
• Broad gene-expression modulation. Russian-programme research has reported that single intranasal Semax administration in rats produces measurable changes in dozens of genes in hippocampus and frontal cortex within minutes, including genes related to vascular function, neurotrophic signalling, and inflammatory pathways.

Why the N-acetyl C-amide modifications matter

Short peptides are typically cleared rapidly in plasma by aminopeptidases (acting on the free N-terminus) and carboxypeptidases (acting on the free C-terminus). The two chemical strategies that cap these termini are:

• N-terminal acetylation, which blocks aminopeptidase access.
• C-terminal amidation, which blocks carboxypeptidase access.

Together these modifications produce an analogue with extended plasma stability and, in published reports, improved blood-brain-barrier penetration relative to the unmodified parent. The same chemical strategy is applied to the N-acetyl variants of selank and epithalon described in separate posts.

Preclinical research highlights

Cerebral ischaemia and stroke models. Russian-programme research has reported neuroprotective effects in rodent and clinical-research stroke models, with reported acceleration of post-stroke functional recovery and elevations in plasma BDNF.

Cognitive and learning endpoints. Rodent studies have reported improvements in spatial learning, memory consolidation, and attentional performance, attributed in part to BDNF and NGF elevations.

Optic nerve and ophthalmologic models. Russian-programme research has reported applications in optic-nerve-injury models, motivating continued interest in CNS-active short peptides in ophthalmology research.

Default-mode-network engagement. Functional-imaging studies have reported changes in resting-state network activity following Semax administration in human research subjects.

Limitations of the evidence base

Several caveats apply:

• The supporting biological literature is concentrated in a Russian research programme, with limited independent Western replication.
• Clinical-trial data exists primarily within the Russian regulatory framework rather than in major Western trial registries.
• Pharmacokinetic comparison data between Semax and the N-acetyl amidated derivative in matched experimental conditions is sparse in the public literature.
• Mechanistic claims around direct gene-expression modulation by short peptides remain controversial in mainstream peptide pharmacology, although the magnitude of reported transcriptional changes following Semax administration is well-documented within the Russian-programme literature.

Current research status

N-Acetyl Semax Amidate is an investigational research peptide outside the Russian regulatory framework. It is not approved by the FDA or EMA. Research interest is concentrated in cognitive enhancement, post-stroke recovery, BDNF biology, and short-peptide CNS pharmacology.

For research-supplier contexts, N-Acetyl Semax Amidate is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• N-Acetyl Semax Amidate is a chemically capped analogue of Semax, a heptapeptide derived from ACTH(4-10) and developed in Russia as a CNS-active short peptide.
• The N-acetyl and C-amide modifications block exopeptidase clearance and are reported to extend stability and improve blood-brain-barrier penetration.
• Reported preclinical effects span post-ischaemic neuroprotection, cognitive and learning endpoints, BDNF and NGF elevation, and broad CNS gene-expression modulation.
• The supporting literature is concentrated in a Russian research programme with limited Western replication.
• Semax is not FDA- or EMA-approved; the N-acetyl amidated derivative is investigational outside the Russian framework.

References

1. Kaplan AYa, Kochetova AG, Nezavibathko VN, et al. Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19(2):115–123.
2. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228.

---

This article is provided for educational and research purposes only. N-Acetyl Semax Amidate is a research peptide. It is not an FDA- or EMA-approved drug and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.